全文获取类型
收费全文 | 2346497篇 |
免费 | 175088篇 |
国内免费 | 3319篇 |
专业分类
耳鼻咽喉 | 32049篇 |
儿科学 | 75896篇 |
妇产科学 | 62687篇 |
基础医学 | 348172篇 |
口腔科学 | 63628篇 |
临床医学 | 211352篇 |
内科学 | 457301篇 |
皮肤病学 | 51730篇 |
神经病学 | 185266篇 |
特种医学 | 88013篇 |
外国民族医学 | 489篇 |
外科学 | 353937篇 |
综合类 | 47559篇 |
现状与发展 | 12篇 |
一般理论 | 848篇 |
预防医学 | 182739篇 |
眼科学 | 54328篇 |
药学 | 175100篇 |
11篇 | |
中国医学 | 4575篇 |
肿瘤学 | 129212篇 |
出版年
2021年 | 18980篇 |
2019年 | 19538篇 |
2018年 | 27057篇 |
2017年 | 20358篇 |
2016年 | 22746篇 |
2015年 | 25640篇 |
2014年 | 36095篇 |
2013年 | 53959篇 |
2012年 | 74674篇 |
2011年 | 79409篇 |
2010年 | 47059篇 |
2009年 | 44564篇 |
2008年 | 74616篇 |
2007年 | 79482篇 |
2006年 | 80296篇 |
2005年 | 77777篇 |
2004年 | 74366篇 |
2003年 | 71691篇 |
2002年 | 69366篇 |
2001年 | 108738篇 |
2000年 | 111452篇 |
1999年 | 93496篇 |
1998年 | 26991篇 |
1997年 | 23661篇 |
1996年 | 24056篇 |
1995年 | 22716篇 |
1994年 | 20894篇 |
1993年 | 19713篇 |
1992年 | 72005篇 |
1991年 | 70071篇 |
1990年 | 68394篇 |
1989年 | 65668篇 |
1988年 | 60302篇 |
1987年 | 59126篇 |
1986年 | 55222篇 |
1985年 | 53010篇 |
1984年 | 39316篇 |
1983年 | 33402篇 |
1982年 | 19859篇 |
1979年 | 35885篇 |
1978年 | 25672篇 |
1977年 | 21253篇 |
1976年 | 20345篇 |
1975年 | 21820篇 |
1974年 | 26151篇 |
1973年 | 24809篇 |
1972年 | 23203篇 |
1971年 | 22043篇 |
1970年 | 20253篇 |
1969年 | 19318篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
Weiyu Ye Anna Olsson-Brown Robert A. Watson Vincent T. F. Cheung Robert D. Morgan Isar Nassiri Rosalin Cooper Chelsea A. Taylor Umair Akbani Oliver Brain Rubeta N. Matin Nicholas Coupe Mark R. Middleton Mark Coles Joseph J. Sacco Miranda J. Payne Benjamin P. Fairfax 《British journal of cancer》2021,124(10):1661
Background Immune checkpoint blockers (ICBs) activate CD8+ T cells, eliciting both anti-cancer activity and immune-related adverse events (irAEs). The relationship of irAEs with baseline parameters and clinical outcome is unclear.Methods Retrospective evaluation of irAEs on survival was performed across primary (N = 144) and secondary (N = 211) independent cohorts of patients with metastatic melanoma receiving single agent (pembrolizumab/nivolumab—sICB) or combination (nivolumab and ipilimumab—cICB) checkpoint blockade. RNA from pre-treatment and post-treatment CD8+ T cells was sequenced and differential gene expression according to irAE development assessed.Results 58.3% of patients developed early irAEs and this was associated with longer progression-free (PFS) and overall survival (OS) across both cohorts (log-rank test, OS: P < 0.0001). Median survival for patients without irAEs was 16.6 months (95% CI: 10.9–33.4) versus not-reached (P = 2.8 × 10−6). Pre-treatment monocyte and neutrophil counts, but not BMI, were additional predictors of clinical outcome. Differential expression of numerous gene pathway members was observed in CD8+ T cells according to irAE development, and patients not developing irAEs demonstrating upregulated CXCR1 pre- and post-treatment.Conclusions Early irAE development post-ICB is associated with favourable survival in MM. Development of irAEs is coupled to expression of numerous gene pathways, suggesting irAE development in-part reflects baseline immune activation.Subject terms: Immunotherapy, Melanoma 相似文献
132.
133.
134.
135.
136.
137.
138.
139.
E. Likotrafiti K. M. Tuohy G. R. Gibson R. A. Rastall 《International journal of food sciences and nutrition》2016,67(2):83-91
The aim of the present study was to evaluate the antimicrobial activity of two synbiotic combinations, Lactobacillus fermentum with short-chain fructooligosaccharides (FOS-LF) and Bifidobacterium longum with isomaltooligosaccharides (IMO-BL), against enterohaemorrhagic Escherichia coli O157:H7 and enteropathogenic E. coli O86. Antimicrobial activity was determined (1) by co-culturing the synbiotics and pathogens in batch cultures, and (2) with the three-stage continuous culture system (gut model), inoculated with faecal slurry from an elderly donor. In the co-culture experiments, IMO-BL was significantly inhibitory to both E. coli strains, while FOS-LF was slightly inhibitory or not inhibitory. Factors other than acid production appeared to play a role in the inhibition. In the gut models, both synbiotics effectively inhibited E. coli O157 in the first vessel, but not in vessels 2 and 3. E. coli O86 was not significantly inhibited. 相似文献
140.